CoChat
Sign Up
Cited by 911Growth Hormone and Insulin-like Growth FactorsHormonal and reproductive studiesPituitary Gland Disorders and Treatments

The DOI matches its Crossref record; 260 of the 260 references it cites were found in a registry or an index.

Human Growth Hormone and Human Aging

CORPAS, EMILIANO, HARMAN, S. MITCHELL, BLACKMAN, MARC R.·1993·Endocrine Reviews
DOI 10.1210/edrv-14-1-20
Open this paper in CoChat — free account

Abstract

UNTIL recently, there has been little scientific inquiry into the physiological significance of, and possible therapy for, GH deficiency in adulthood. This was because the lack of efficacy in humans of animal-derived (e.g.1 bovine or porcine) GH and the limited supply of human cadaveric GH restricted use of exogenous GH to treatment of GHdeficient children. The availability of recombinant human GH (rhGH) has led to a renewal of scientific and clinical interest in investigating wider indications for GH administration. It is now recognized that GH deficiency may exert adverse metabolic effects in adults with panhypopituitarism, and that these effects can be reversed or attenuated by treatment with rhGH (1, 2). Recently, it has also become apparent that, with advancing age, an increasing proportion of men and women with no clinical evidence of pituitary pathology show decreases in GH secretion and serum levels of insulin-like growth factor-I (IGF-I) (3, 4). Because GH deficiency (1, 2) and normal aging (5) are both associated with decreases in protein synthesis and percent of lean body and bone mass, and with increases in percent of body fat, it is possible that reduced GH secretion and IGF-I levels might account, at least in part, for one or more of the above effects of aging, and that some older people might benefit from treatment with rhGH. In this regard, in several recent studies, administration of rhGH for periods varying from a few weeks to 6 months has resulted in improvements in nitrogen balance, an increase in lean body mass, and a decrease in percent body fat in older persons with low IGF-I levels (3, 4, 6, 7). We review herein the published work describing the alterations in GH and IGF-I production with increasing age, and the methods, benefits, and risks of GH treatment of older persons in the light of new knowledge regarding basic physiology of GH secretion and action. We also attempt to point out areas requiring further investigations.

Overview

Integrity signals

Registry

Crossref · 10.1210/edrv-14-1-20

Cites

260 of 260 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 911

Related

See all

Metadata

Authors
CORPAS, E., HARMAN, S. M., & BLACKMAN, M. R.
Affiliations
National Institutes of Health (US)
Corresponding author
HARMAN, S. MITCHELL
ORCID
HARMAN, S. MITCHELL
Venue
Endocrine Reviews
Publisher
The Endocrine Society
Published
1993-02
Volume
14
Issue
1
Pages
20-39
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
DOI
10.1210/edrv-14-1-20
OpenAlex
W1964005327
Cited by
911
References
260
Citations by year
2026: 4 · 2025: 12 · 2024: 4 · 2023: 8 · 2022: 7 · 2021: 12 · 2020: 19 · 2019: 16 · 2018: 14 · 2017: 16 · 2016: 11 · 2015: 19 · 2014: 18 · 2013: 18 · 2012: 24
FWCI
26.77
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrine Reviews (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
Keywords
human growth hormone, aging, recombinant human growth hormone, growth hormone deficiency, insulin-like growth factor I, older adults, lean body mass, fat mass, nitrogen balance, growth hormone secretion, panhypopituitarism, growth hormone therapy
MeSH terms
Adult, Aging, Animals, Humans, Immune System, Insulin-Like Growth Factor I, Receptors, Somatotropin, Risk Factors, Growth Hormone, Growth Hormone-Releasing Hormone, Receptor, IGF Type 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review